acetylcholine 35
and aggression 40
adrenergic blockers 76
affective disorder 19
aggression
definition 2
genes associated with
5HTTLPR 47, 48
COMT 46, 48
FKBP5 48
MAO-A see MAO-A gene
genetics 23
impulsive 2, 3, 15, 28
inheritance 41
mechanisms of 34
neurotransmitter systems involved in 23, 24, 35
acetylcholine 40
dopamine 36
GABA 39
glutamate 39
serotonin 37
serotonin receptors 38
predisposition 8
psychopathic 2, 5
psychotic 2, 4, 29
reactive 2, 3
treatment 49–79
amygdala 27, 29, 35
anterior cingulate cortex 27
anticonvulsants 73
antidepressants 74
antipsychotics 51–72
atypical 57–59
binding profiles 58–59
high-dose monotherapy 61–71
molecular binding profiles 58
side effects 58
dopamine D2 receptor occupancy 52
high-dose monotherapy 54, 72
pharmacokinetics and pharmacodynamics 53
polypharmacy 54, 57
time to treat 55
treatment algorithm 56
see also individual drugs
antisocial personality disorder (ASPD) 31
reduced gray matter volume 33
aripiprazole
binding profile 58
dose range 71
high-dose monotherapy 67
asenapine
binding profile 58
dose range 71
high-dose monotherapy 69
attention deficit hyperactivity disorder (ADHD) 28
atypical antipsychotics 57–59
binding profiles 58–59
high-dose monotherapy 61–71
dose range 71
molecular binding profiles 58
side effects 58
see also antipsychotics
benzodiazepines 78
bipolar disorder
and substance abuse 8
and violent behavior 19
borderline personality disorder 28
bottom-up limbic drive 25, 27
suppression of 50
Brøset Violence Checklist (BVC) 21
carbamazepine 73
catechol-O-methyltransferase see COMT
child abuse
MAO-A gene 44
and violence 7
citalopram 74
Classification of Violence Risk (COVR) 21
Clinically Feasible Iterative Classification Tree (ICT-CF) 21
clozapine
binding profile 58
dose range 71
high-dose monotherapy 61
cognitive behavioral therapy 79
cognitive dysfunction 18
testosterone-induced 16
command hallucinations 4
COMT 46, 48
conduct disorder 31
cortical control centers 25, 26
counseling 79
delusions 4
dialectical behavioral therapy 79
dopamine 35
and aggression 36
D2 receptor occupancy 52, 60
dose ranges of atypical antipsychotics 71
domestic violence 7
emotional hypersensitivity 3
FKBP5 48
fluoxetine 74
GABA see gamma-aminobutyric acid
gamma-aminobutyric acid (GABA) 35
and aggression 39
gender
sexual dimorphism
MAO-A gene 44
reversal in schizophrenia 12
and testosterone exposure 13
"sexual unmorphism" 12
and violence 11
genes associated with aggression
5HTTLPR 47, 48
COMT 46, 48
FKBP5 48
MAO-A see MAO-A gene
genetics of aggression 23
glutamate 35
and aggression 39
grandiosity 4
gray matter, reduced volume 33
Hare Psychopathy Checklist: Screening Version (PCL:SV) 21
Hare Psychopathy Checklist–Revised (PCL-R) 21
heterogeneity of violence 2
high-dose monotherapy
atypical antipsychotics 61–71
conventional antipsychotics 72
hippocampus 27
Historical Clinical Risk Management (HCR-20) 21
hostility, testosterone-induced 16
5HTTLPR 47, 48
hypothalamic–pituitary–adrenal (HPA) axis 7
hypothalamus 27
iloperidone
binding profile 58
dose range 71
high-dose monotherapy 68
impulsive aggression 2, 3
MAO-A gene 45
neurocircuitry 28
and serotonin 15
and testosterone 15
inheritance of aggression 41
interpersonal skills training 79
lamotrigine 73
limbic control centers 25, 27

© in this web service Cambridge University Press www.cambridge.org
violence: index

- lithium 73
- lurasidone
  - binding profile 58
  - dose range 71
  - high-dose monotherapy 70
- MAO-A gene 42, 48
  - child abuse 44
  - polymorphisms, and impulsivity 45
  - sexual dimorphism 44
  - testosterone regulation 43
- men
  - childhood abuse 44
  - schizophrenia in 12
  - violent behavior 11
- Modified Screening Tool (MST) 21
- monoamine oxidase A ("warrior gene")
  - see MAO-A gene
- mood stabilizers 73
  - see also individual drugs
- naltrexone 77
- neurobiology 23
  - aggression 24
  - impulsive 29
    - neurotransmitter systems 35
    - psychopathic 32
    - psychotic 29
- bottom-up limbic drive 25, 27
- impaired neurotransmission 24
- testosterone effects 17
- top-down cortical brake 25, 26
- nonpharmacological treatment 79
- norepinephrine 35
- nucleus accumbens 29
- olanzapine
  - binding profile 58
  - dose range 71
  - high-dose monotherapy 62
  - opiate antagonists 77
  - orbitofrontal cortex 26
  - oxcarbazepine 73
- paliperidone
  - binding profile 58
  - dose range 71
  - high-dose monotherapy 64
- paranoid 4
- phenytoin 73
- posttraumatic stress disorder (PTSD) 28
- predatory gain 5
- prediction of violence 22
- prefrontal cortex 26, 35
- psychopathic aggression 2, 5
- neurocircuitry 32
- Psychopathology Checklist–Revised (PCL-R) 30
- psychopathy 30
  - antisocial personality disorder 31
  - conduct disorder 31
  - reduced gray matter volume 33
  - psychosis 4
- psychosocial interventions 79
- psychotic aggression 2, 4
- neurocircuitry 29
- quetiapine
  - binding profile 58
  - dose range 71
  - high-dose monotherapy 65
- reactive aggression 2, 3
- remorse, lack of 5
- risk assessment 21, 22
- risk factors for violence 6
- affective disorder 19
- child abuse 7
- cognitive dysfunction 18
- gender 11
- schizophrenia 9, 10
- substance abuse 8
- treatment nonadherence 20
- risperidone
  - binding profile 58
  - dose range 71
  - high-dose monotherapy 63
- schizophrenia
  - delusions 4
    - "sexual unmorphism" 12
    - and substance abuse 8
testosterone in 13, 16, 17
cognition and hostility 16
effects on neurotransmission 17
treatment nonadherence 20
violent behavior 9
cost of 10
selective serotonin reuptake inhibitors (SSRIs) 74
serotonin 35
and aggression 37
impulsive aggression 15
neurotransmission, testosterone effects 17
serotonin receptors 38
serotonin transporter gene see 5HTTLPR
sertaline 74
sexual dimorphism
MAO-A gene 44
reversal in schizophrenia 12
and testosterone exposure 13
side effects of atypical antipsychotics 58
stimulants 75
substance abuse 29
and violence 8
testosterone
and impulsive aggression 15
regulation of MAO-A gene 43
in schizophrenia 13
cognition and hostility 16
effects on neurotransmission 17
and violent behavior 14
thalamus 27
threat 4
exaggerated perception 3
top-down cortical brake 25, 26
suppression of 50
topiramate 73
treatment 49–79
adrenergic blockers 76
antidepressants 74
antipsychotics 51–72
benzodiazepines 78
mood stabilizers 73
nonadherence 20
nonpharmacological 79
opiate antagonists 77
stimulants 75
see also individual drugs
valproate 73
ventral tegmental area 29
violence
 genetics 23
heterogeneity of 2
neurobiology 23
patient prediction 22
predisposition to 8
risk assessment 21, 22
risk factors 6
affective disorder 19
child abuse 7
cognitive dysfunction 18
gender 11
substance abuse 8
treatment nonadherence 20
in schizophrenia 9, 10
cost of 10
testosterone exposure 13, 16, 17
treatment nonadherence 20
testosterone effects 14
treatment 49–79
see also aggression
Violence Risk Assessment Guide (VRAG) 21
Violence Risk Scale (VRS) 21
Violence Risk Screening-10 (V-RISK-10) 21
“warrior gene” (MAO-A) 42
women
childhood abuse 44
schizophrenia in 12
violent behavior 11
ziprasidone
binding profile 58
dose range 71
high-dose monotherapy 66